A Shared Vision for Elevated, Personalized Medicine

The Challenge

Octane broke through to a new frontier in personalized medicine with the invention of Cocoon, an automated cell and tissue therapy production system designed to efficiently manufacture patient-scale and patient-specific cellular implants.

Octane launched Octane Biotech to develop, validate and manufacture the Cocoon system. But to advance Cocoon cell therapy into clinical applications on a global scale, Octane needed a partner with international reach and a shared vision to promote personalized medicine.

The Game Changer

After meeting with numerous prospective partners, Octane found its match in the Lonza Group in Basel, Switzerland. Lonza had explored personalized medicine previously but could not find a viable platform to support its goals.

With its acquisition of a majority stake in Octane Biotech as a cornerstone, Lonza launched its personalized medicine strategy.

The Impact

The Octane + Lonza partnership advances Octane’s vision to make cost-effective and clinically-scaleable personalized medicine the standard of care for all. Lonza leads commercialization activities for all Cocoon applications with the exception of orthopedic applications, which remain with Octane Orthobiologics Inc.Through a comprehensive, international technical support program, Lonza works with multiple clients to integrate Cocoon into optimized clinical and commercial cell therapy manufacturing programs, particularly in immunotherapy.